Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Johnson & Johnson's Talvey (talquetamab) accepted in Scotland for relapsed and refractory multiple myeloma via Ph1/2
Antibody, cancer, bispecific antibody, multiple myeloma, GPRC5D, CD3 - Read more

Zai Lab receives China NMPA approval for TIVDAK (tisotumab vedotin) in recurrent or metastatic cervical cancer based on Ph3 data
Antibody-drug conjugate, cancer, cervical cancer, tisotumab vedotin, tissue factor target - Read more

AlzeCure Pharma, Eli Lilly partner on Alzheimer's Alzstatin ACD680, $10M upfront, $1B+ milestones
Licensing deal, neurological, small molecule, milestone payments, royalties - Read more

FloBiotech, UCLA Health license DDL-357 small-molecule therapeutic targeting neurodegenerative disease protective pathways
Licensing deal, neurological, small molecule, research collaboration - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Eli Lilly's (retatrutide) Ph3 data shows reduced knee osteoarthritis pain and sleep apnea events, widening obesity lead
Small molecule, metabolic, obesity, incretin, GLP-1, type 2 diabetes - Read more

AstraZeneca's (elecoglipron) Ph2 data show blood glucose, weight reductions in type 2 diabetes and obesity ahead of Ph3
Small molecule, metabolic, GLP-1 receptor agonist, type 2 diabetes, obesity - Read more

Eli Lilly submits Foundayo (orforglipron) to FDA for type 2 diabetes following Ph3 ACHIEVE program victories
Small molecule, metabolic, GLP-1 receptor agonist, type 2 diabetes, orforglipron, weight management - Read more

Gilead, Merck & Co.'s (islatravir/lenacapavir) meets primary endpoint in Ph3 trials for human immunodeficiency virus type 1
Small molecule, infectious disease, HIV, combination therapy, once-weekly dosing, capsid inhibitor - Read more

CeQur raises $100M Series E to accelerate insulin patch commercial growth
Diabetes, medical device, insulin delivery, commercial-stage - Read more

Parabilis Medicines plans up to $636.8M IPO, advancing rare tumor candidate zolucatetide
Oncology, rare disease, peptide therapeutics, clinical-stage, undruggable targets - Read more

City Therapeutics banks $99.5M to advance next-gen RNAi drug pipeline
RNAi, cardiovascular, rare disease, clinical-stage - Read more

Harness Therapeutics awarded Michael J. Fox Foundation grant to advance Parkinson's disease GBA1 programme
Neurological, ASO, platform technology, Parkinson's disease, neurodegenerative - Read more

Rejuvenate Bio raises $6M in financing, developing gene therapies for age-related and chronic diseases
Gene therapy, longevity, chronic disease, companion animals, platform technology - Read more

Roche maintains €600M ($692.88M) Germany diagnostics investment but warns new healthcare policy threatens future spending
Diagnostics, healthcare policy, investment, operational - Read more

Novo Nordisk's oral Wegovy pill surpasses 3 million prescriptions, reaching 80% new GLP-1 patients
Small molecule, obesity, competitive, revenue impact - Read more

GSK to acquire Nuvalent Bio for $10.6B, securing precision oncology pipeline in industry's second-largest deal
Small molecule, oncology, strategic, major transaction - Read more

GNI Group to acquire Ayumi Pharmaceutical for $280M, expanding Japan commercial footprint
Small molecule, pain management, major transaction, strategic - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Bial discontinues (BIA 28-6156) development after Ph2b miss in GBA1-variant Parkinson's disease patients
Small molecule, neurological, Parkinson's disease, GCase activator, GBA1 variant, disease-modifying therapy - Read more

Gilead's Trodelvy (sacituzumab govitecan) Ph3 trial fails in first-line PD-L1-high non-small cell lung cancer
Antibody-drug conjugate, cancer, non-small cell lung cancer, TROP2, combination therapy, ADC - Read more

AstraZeneca reprimanded again by UK watchdog over employees' LinkedIn likes promoting cancer drug Lynparza
Small molecule, oncology, regulatory, operational, compliance - Read more

Sangamo Therapeutics explores strategic alternatives amid financial strain, with shares delisted and cash runway through Q3 2026
Gene therapy, rare disease, strategic, financial - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here